Be part of the knowledge.™

Breast Cancer and Breast Health

31

LikeLikedUnlike

Episodes 1-15 of 42

Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
CME/CE Live Broadcast
Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
March 21, 2025
12:00 PM - 01:00 PM EDT
1.00 credits Learn more
Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
CME/CE Live Broadcast
Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
March 28, 2025
03:00 PM - 04:00 PM EDT
1.00 credits Learn more
CME/CE Meeting
From Risk to Resilience: An Interactive Sharing of Best Practices for Improving Outcomes in Early-Stage ER+/HER2- Breast Cancer
April 11, 2025
Denver, Colorado
Learn more
From Risk to Resilience: An Interactive Sharing of Best Practices for Improving Outcomes in Early-Stage ER+/HER2- Breast Cancer
CME/CE Live Broadcast
From Risk to Resilience: An Interactive Sharing of Best Practices for Improving Outcomes in Early-Stage ER+/HER2- Breast Cancer
April 11, 2025
09:00 PM - 10:30 PM ET
Learn more
MinuteCE®
Optimizing Ovarian Function Suppression in Hormone Receptor-Positive Breast Cancer: Best Practices for the Community Clinician
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 credits 4 episodes
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
CME/CE
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
- Javier Cortes, MD, PhD
  Peer
- Hope S. Rugo, MD, FASCO
  Peer
0.50 credits
Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches
MinuteCE®
Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches
- Carey Anders, MD, FASCO
  Peer
1.00 program credits
Understanding CNS Lesions in HER2+ Metastatic Breast Cancer
MinuteCE®
Understanding CNS Lesions in HER2+ Metastatic Breast Cancer
- Sarah Sammons, MD
  Peer
1.00 program credits
MinuteCE®
HER2-Expressing MBC In Depth: The Latest Advances in Targeted Therapies and Brain Metastases Management
- Carey Anders, MD, FASCO
  Peer
- Sarah Sammons, MD
  Peer
1.00 credits 7 episodes
Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer
MinuteCE®
Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer
- Carey Anders, MD, FASCO
  Peer
- Sarah Sammons, MD
  Peer
1.00 program credits
HER2-Targeted TKI Combinations in Second-Line and Beyond MBC
MinuteCE®
HER2-Targeted TKI Combinations in Second-Line and Beyond MBC
- Sarah Sammons, MD
  Peer
1.00 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended